Literature DB >> 10984309

Heterozygous mutation in the WSXWS equivalaent motif of the growth hormone receptor in a child with poor response to growth hormone therapy.

M T Tauber1, V Porra, F Dastot, C Molinas, S Amselem, S Cholin, P Rochiccioli, E Bieth.   

Abstract

Besides complete GH insensitivity syndrome (GHIS) described by Laron, clinical and molecular evidences have accumulated concerning partial GHIS. We studied GH receptor (GHR) gene in children who show poor response to GH treatment and detected a patient with a heterozygous mutation in exon 7 leading to the Y222H substitution. This missense mutation, located in the YGEFS motif of the GHR equivalent to the WSXWS motif highly conserved throughout all members of the cytokine receptor family, has not been described so far. Although we cannot conclude on the deleterious effect of this mutation, there are several lines of evidence suggesting that it could account for the partial GH insensitivity: (i) hormonal data including IGF-I generation test; (ii) molecular data - no other mutation was identified in the coding sequence, the father who has the same mutation is short, the brother did not inherit the mutated allele and was of normal height.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10984309     DOI: 10.1016/s1096-6374(98)80113-5

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  2 in total

1.  Natural allelic variation of the IL-21 receptor modulates ischemic stroke infarct volume.

Authors:  Han Kyu Lee; Sehoon Keum; Huaxin Sheng; David S Warner; Donald C Lo; Douglas A Marchuk
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

2.  Crystal structure of interleukin-21 receptor (IL-21R) bound to IL-21 reveals that sugar chain interacting with WSXWS motif is integral part of IL-21R.

Authors:  Ole J Hamming; Lishan Kang; Anders Svensson; Jesper L Karlsen; Henrik Rahbek-Nielsen; Søren R Paludan; Siv A Hjorth; Kent Bondensgaard; Rune Hartmann
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.